Literature DB >> 24778452

Human cardiac extracellular matrix supports myocardial lineage commitment of pluripotent stem cells.

Barbara Oberwallner1, Andreja Brodarac1, Petra Anić1, Tomo Šarić2, Katharina Wassilew3, Klaus Neef4, Yeong-Hoon Choi4, Christof Stamm5.   

Abstract

OBJECTIVES: Cross-talk between organ-specific extracellular matrix (ECM) and stem cells is often assumed but has not been directly demonstrated. We developed a protocol for the preparation of human cardiac ECM (cECM) and studied whether cECM has effects on pluripotent stem cell differentiation that may be useful for future cardiac regeneration strategies in patients with end-stage heart failure.
METHODS: Of note, 0.3 mm-thick cECM slices were prepared from samples of myocardium from patients with end-stage non-ischaemic dilated cardiomyopathy, using a three-step protocol involving hypotonic lysis buffer, sodium dodecyl sulphate (SDS) and foetal bovine serum (FBS). Murine embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs) and mesenchymal stromal cells (MSCs) were seeded and grown in standard culture, on cECM or on non-specific ECM preparations (Matrigel® or Geltrex®). Cell attachment, apoptosis induction (Caspase 3/7 activity) and metabolic activity (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium conversion) were followed. Transcriptional activation of genes involved in pluripotency; early and late myocardial development; and endothelial, ectodermal or endodermal commitment were monitored by quantitative real-time polymerase chain reaction (rtPCR). Protein expression of selected markers was confirmed by immunohistology.
RESULTS: cECM supported the proliferation of ESCs and iPSCs, and Caspase 3/7 activity was significantly lower compared with standard culture. Cardiac lineage commitment was favoured when ESCs or iPSCs were grown on cECM, as evidenced by the significantly increased mRNA expression of cardiac alpha myosin heavy polypeptide 6 (Myh6), cardiac troponin T2 (Tnnt2) and NK2 homeobox 5 (Nkx2.5) as well as positive immunohistology for cardiac troponin T and heavy-chain cardiac myosin protein. In contrast, Matrigel or Geltrex did not induce cardiac-specific markers. MSCs showed no evidence of cardiomyocyte differentiation.
CONCLUSIONS: Human cardiac ECM seems to direct differentiation of pluripotent stem cells towards a cardiomyocyte phenotype. This phenomenon supports the use of cardiac ECM preparations for guided stem cell differentiation and myocardial repair, and may ultimately increase the therapeutic efficacy of cell therapy in heart failure patients.
© The Author 2014. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Differentiation; Extracellular matrix; Pluripotent cells; Recellularization; Stem cells

Mesh:

Substances:

Year:  2014        PMID: 24778452     DOI: 10.1093/ejcts/ezu163

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  24 in total

1.  Impact of decellularization on porcine myocardium as scaffold for tissue engineered heart tissue.

Authors:  Xiaofeng Ye; Haozhe Wang; Wenhui Gong; Shen Li; Haiqing Li; Zhe Wang; Qiang Zhao
Journal:  J Mater Sci Mater Med       Date:  2016-02-17       Impact factor: 3.896

2.  The cytoprotective capacity of processed human cardiac extracellular matrix.

Authors:  Benjamin Kappler; Petra Anic; Matthias Becker; Andreas Bader; Kristin Klose; Oliver Klein; Barbara Oberwallner; Yeong-Hoon Choi; Volkmar Falk; Christof Stamm
Journal:  J Mater Sci Mater Med       Date:  2016-06-07       Impact factor: 3.896

Review 3.  Decellularized Extracellular Matrix Materials for Cardiac Repair and Regeneration.

Authors:  Donald Bejleri; Michael E Davis
Journal:  Adv Healthc Mater       Date:  2019-02-04       Impact factor: 9.933

Review 4.  Extracellular matrix hydrogel therapies: In vivo applications and development.

Authors:  Martin T Spang; Karen L Christman
Journal:  Acta Biomater       Date:  2017-12-20       Impact factor: 8.947

5.  Processing of Human Cardiac Tissue Toward Extracellular Matrix Self-assembling Hydrogel for In Vitro and In Vivo Applications.

Authors:  Matthias Becker; Janita A Maring; Barbara Oberwallner; Benjamin Kappler; Oliver Klein; Volkmar Falk; Christof Stamm
Journal:  J Vis Exp       Date:  2017-12-04       Impact factor: 1.355

6.  Wnt/β-Catenin and MEK-ERK Signaling are Required for Fibroblast-Derived Extracellular Matrix-Mediated Endoderm Differentiation of Embryonic Stem Cells.

Authors:  Kevin Dzobo; Matjaz Vogelsang; M Iqbal Parker
Journal:  Stem Cell Rev Rep       Date:  2015-10       Impact factor: 5.739

Review 7.  Translational aspects of cardiac cell therapy.

Authors:  Cheng-Han Chen; Konstantina-Ioanna Sereti; Benjamin M Wu; Reza Ardehali
Journal:  J Cell Mol Med       Date:  2015-06-27       Impact factor: 5.310

Review 8.  A Concise Review on Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Personalized Regenerative Medicine.

Authors:  Pallavi Pushp; Diogo E S Nogueira; Carlos A V Rodrigues; Frederico C Ferreira; Joaquim M S Cabral; Mukesh Kumar Gupta
Journal:  Stem Cell Rev Rep       Date:  2020-10-23       Impact factor: 5.739

9.  Three-dimensional poly-(ε-caprolactone) nanofibrous scaffolds directly promote the cardiomyocyte differentiation of murine-induced pluripotent stem cells through Wnt/β-catenin signaling.

Authors:  Yan Chen; Di Zeng; Lu Ding; Xiao-Li Li; Xiong-Tao Liu; Wen-Ju Li; Ting Wei; Song Yan; Jiang-Hui Xie; Li Wei; Qiang-Sun Zheng
Journal:  BMC Cell Biol       Date:  2015-09-03       Impact factor: 4.241

10.  Fibroblast-Derived Extracellular Matrix Induces Chondrogenic Differentiation in Human Adipose-Derived Mesenchymal Stromal/Stem Cells in Vitro.

Authors:  Kevin Dzobo; Taegyn Turnley; Andrew Wishart; Arielle Rowe; Karlien Kallmeyer; Fiona A van Vollenstee; Nicholas E Thomford; Collet Dandara; Denis Chopera; Michael S Pepper; M Iqbal Parker
Journal:  Int J Mol Sci       Date:  2016-08-03       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.